Sarepta slumps after approved muscle disorder drugs fail confirmatory trial

Sarepta Therapeutics

04/11/2025 12:47

** Shares of Sarepta Therapeutics SRPT.O fall 36.4% to $15.55 premarket

** Co said on Monday two of its approved drugs for a muscle wasting disorder failed in a key study

** SRPT was testing its therapies, Amondys 45 and Vyondys 53, in a trial aimed at seeking confirmation of their effectiveness in treating Duchenne muscular dystrophy, a condition that causes skeletal and heart muscle weakness that quickly gets worse with time

** Adds the trial, which was conducted over a nine-year period, was impacted by the COVID 19 pandemic

** Confirmatory trials are considered a key part of regulatory submissions for a full approval of drugs

** We do not anticipate the FDA pulling Vyondys and Amondys from the market, brokerage Mizuho says

** Up to last close, stock down ~80% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))